Company Continues to Expand Scientific and Commercial Leadership
CAMBRIDGE, Mass., Sept. 17 /PRNewswire/ -- Millennium: The Takeda
Oncology Company today announced the addition of two new executives. Claire
Thom, Pharm.D., is the Senior Vice President, Portfolio Management and
Isabelle Mercier joins Millennium as Vice President, Marketing for the
Company's Commercial organization.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080827/NEW076LOGO )
"We are very excited to have these two, highly-successful
pharmaceutical executives join the Millennium team to help lead the
organization towards becoming a top three global oncology company," said
Deborah Dunsire, M.D., President and CEO, Millennium. "Claire and Isabelle
will offer insight and perspective to effectively develop and market the
molecules in our expanding oncology pipeline as well as bring a proven
level of entrepreneurship and innovative thinking."
Claire Thom, Senior Vice President, Portfolio Management joins
Millennium with nearly 20 years of experience in drug development, new
product planning and marketing. In this role, she will be responsible for
the oncology portfolio management process. Previously, Claire was
responsible for the oversight and implementation of the global therapeutic
area strategies for oncology, urology and gynecology franchises of Takeda
Pharmaceutical Company in Japan. She also held several senior research and
development as well as product planning positions at Takeda Global Research
& Development and Takeda Pharmaceuticals North America. Prior to Takeda,
Claire held positions of increasing responsibility at G.D. Searle and
Company in the areas of global new product planning and US oncology
marketing. She earned a Bachelor of Pharmacy degree with high honors and a
Doctorate of Pharmacy with honors from the University of Illinois, Chicago.
Isabelle Mercier brings more than 16 years of global pharmaceutical
marketing experience. As Vice President of Marketing, she will lead and
develop US and global marketing strategy for the commercialization of late
phase development products as well as oncology marketed products, including
VELCADE(R) (bortezomib) for Injection for patients with multiple myeloma.
Isabelle joins Millennium from sanofi-aventis and most recently served as
Vice President of Taxotere Marketing. Additionally, she has US and global
experience in sales, clinical research and oncology product launches from
Sanofi-Synthelab and SangStat Medical Corporation. Isabelle earned dual
Bachelor of Science degrees in Biochemistry and Clinical Biology from
Universites Catholiques in Lyon, France as well as a Bachelor of Science
degree in Genetic & Cellular Biology from l'Universite Lyon I in Lyon,
France and an advanced degree in Biotechnologies from Universites
Catholiques.
About Millennium
Millennium: The Takeda Oncology Company, a leading biopharmaceutical
company based in Cambridge, Mass., markets VELCADE, a novel cancer product,
and has a robust clinical development pipeline of product candidates.
Millennium research, development and commercialization activities are
focused in oncology. Additional information about Millennium is available
through its website, http://www.millennium.com.
Media Contact:
Karen Gobler
(617) 444-1392
karen.gobler@mpi.com
SOURCE Millennium: The Takeda Oncology Company
 back to top
Related links:
http://www.millennium.com/
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20080827/NEW076LOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
http://www.prnewswire.com/comp/114562.html /
CONTACT:
Karen Gobler of Millennium: The Takeda
Oncology Company, +1-617-444-1392, karen.gobler@mpi.com
|
